Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Platinum Resistant Epithelial Ovarian Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT01970722
What this trial is testing

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Who this might be right for
FIGO Stage IVA Ovarian CancerFIGO Stage IVB Ovarian CancerPlatinum-Resistant Ovarian Carcinoma+26 more
City of Hope Medical Center 40
Testing effectiveness (Phase 2)Study completedNCT00022347
What this trial is testing

TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Memorial Sloan Kettering Cancer Center
Large-scale testing (Phase 3)Looking for participantsNCT06994195
What this trial is testing

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 450
Testing effectiveness (Phase 2)WithdrawnNCT06393751
What this trial is testing

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+20 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT02364713
What this trial is testing

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Who this might be right for
Fallopian Tube CarcinosarcomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+24 more
Mayo Clinic 17
Early research (Phase 1)Ended earlyNCT01494012
What this trial is testing

Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

Who this might be right for
Recurrent Ovarian Epithelial CancerRecurrent Ovarian Germ Cell TumorMalignant Tumor of Peritoneum+2 more
Stanford University 1
Large-scale testing (Phase 3)Study completedNCT01204749
What this trial is testing

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Amgen 919
Testing effectiveness (Phase 2)Active Not RecruitingNCT03449108
What this trial is testing

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Large-scale testing (Phase 3)WithdrawnNCT04795596
What this trial is testing

Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers

Who this might be right for
Ovarian CancerRecurrent Ovarian Carcinoma
Menoufia University
Testing effectiveness (Phase 2)UnknownNCT05272462
What this trial is testing

Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer
Loyola University 34
Early research (Phase 1)Ended earlyNCT03691376
What this trial is testing

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+9 more
Roswell Park Cancer Institute 4
Testing effectiveness (Phase 2)Study completedNCT02440425
What this trial is testing

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute 42
Testing effectiveness (Phase 2)Ended earlyNCT01936974
What this trial is testing

(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

Who this might be right for
Ovarian CarcinomaFallopian Tube CarcinomaPeritoneal Carcinoma
Western Regional Medical Center 7
Testing effectiveness (Phase 2)Ended earlyNCT00084448
What this trial is testing

Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Study completedNCT00003449
What this trial is testing

Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
University of Southern California 35
Testing effectiveness (Phase 2)WithdrawnNCT03281681
What this trial is testing

A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
DelMar Pharmaceuticals, Inc.
Early research (Phase 1)Study completedNCT02898207
What this trial is testing

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Who this might be right for
Metastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid NeoplasmMetastatic Primary Peritoneal Serous Adenocarcinoma+16 more
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Study completedNCT01402271
What this trial is testing

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
European Organisation for Research and Treatment of Cancer - EORTC 88
Early research (Phase 1)Ended earlyNCT03924245
What this trial is testing

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Who this might be right for
Fallopian Tube CancerFallopian Tube CarcinosarcomaFallopian Tube Clear Cell Adenocarcinoma+10 more
Vanderbilt-Ingram Cancer Center 3
Next Page